Meta Analysis of the Efficacy and Safety of Urate Reabsorption Inhibitors in the Treatment of Gout and Hyperuricemia

LIU Ruilin; ZHOU Quan; LI Jigao; DU Mingrui

doi:10.3969/j.issn.1004-437X.2025.14.003

Abstract：Objective To analyze the efficacy and safety of urate reabsorption inhibitors in the treatment of gout and hyperuricemia using meta-analysis,in order to provide evidence-based evidence for the treatment of gout and hyperuricemia.Methods Through computer searches of domestic and foreign databases(such as CNKI,Wanfang,PubMed,etc.),clinical randomized controlled trials related to the treatment of gout and hyperuricemia with benzbromarone were included.The search period was from the establishment of each database until June 2023.The data extraction and quality evaluation of the literature were carried out,and the meta-analysis of the result data was carried out by Review Manager 5.0 software.Results Finally,12 articles were included,of which 6 articles analyzed the clinical efficacy,4 articles analyzed blood urea nitrogen,7 articles analyzed serum creatinine,10 articles analyzed blood uric acid,and 6 articles analyzed adverse reactions,all of which could extract effective data.After entering the outcome indicators,meta-analysis results showed that compared with allopurinol or low purine diet treatment,the total effective rate of benzbromarone in the treatment of gout and hyperuricemia was higher[OR=3.350,95％ CI(1.660-6.790),P＜0.001],and blood urea nitrogen,creatinine,and uric acid levels were lower[MD was-1.160,-7.700,and-71.750,respectively;95％ CI was(1.660-6.790),(-1.360--0.960),and(-97.620--45.880),P＜0.05].Compared with allopurinol treatment,the incidence of adverse reactions in the treatment of gout and hyperuricemia with benzbromarone was lower[OR=0.380,95％CI(0.200-0.700),P=0.002].Conclusion Benzbromarone can effectively reduce blood urea nitrogen,creatinine,and uric acid levels in the treatment of gout and hyperuricemia,improve efficacy,and the safety is acceptable.